Clinical trial NCT02095964: HDL-C in Cardiac Syndrome X
Official title: HDL-Cholesterol is Inversely Related With Inflammation in Cardiac Syndrome X
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Diseases
Heart Diseases
Myocardial Ischaemia
Unstable Angina
Microvascular Angina
Keywords: cardiac syndrome X
inflammation
dyslipidemia
Lead sponsor: Bursa Yüksek İhtisas Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2014-03-26
Enrollment: 710
Sex: ALL
Minimum age (years): 47
Maximum age (years): 58
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: CSX was defined as typical chest pain during rest or effort, abnormal test result for exercise ECG and myocardial perfusion scintigraphy, and the presence of angiographically normal epicardial coronary arteries. Control group was selected from volunteers presented to our hospital with the complaint of typical anginal chest pain who had no ischemia on myocardial perfusion scintigraphy or during the treadmill exercise test, had similar risk profile with the patients (diabetes, hypertension, age, gender) and had normal epicardial coronaries at coronary angiography.

Brief summary: High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver\[10\]. HDL-C promotes endothelial generation of nitric oxide (NO) and improves endothelial function and arterial vasoreactivity\[11\]. In several studies, lower HDL-C level was reported to be associated with increased coronary artery disease (CAD) risk\[12-14\]. HDL-C also has anti- inflammatory and anti-oxidant activities\[15,16\]. Concerning anti-inflammatory activity, HDL-C inhibits the activation of monocytes/macrophages and neutrophils\[17,18\] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin\[15\].

In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X (CSX).


Eligibility criteria: Inclusion Criteria:

* Must be able to get exercise stress test
* Must be able to have coronary angiography
* Clinical diagnosis of typical anginaduring rest or effort
* Abnormal test result for exercise ECG or myocardial perfusion scintigraphy
* Must have of angiographically normal epicardial coronary arteries

Exclusion Criteria:

* Patients with valvular heart disease (mitral stenosis and moderate to severe mitral regurgitation
* Patients with moderate to severe aortic stenosis and regurgitation including mitral annular calcification)
* Patients with heart failure (left ventricular ejection fraction \<50%)
* Patients with congenital heart disease, cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy
* Patients with cardiac surgery
* Patients with thyroid disease
* Patients with anemia
* Patients with pulmonary diseases
* Patients with infectious diseases (locally or systemic)

Primary outcomes:
measure: HDL-Cholesterol
timeFrame: 6 MONTHS
measure: Cardiac Syndrome X
timeFrame: 6 months
measure: Inflammation
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: